For research and educational purposes only. Not medical advice.
KPV Reference
Educational, not medical advice reference for KPV: Recovery, Immune; regulatory status, evidence posture, source review, and schedule notes. Als…
Reference summary
Preclinical literature documents anti-inflammatory effects in rodent colitis models and transport via PepT1 in intestinal epithelium. Direct human clinical evidence for standalone KPV protocols is limited.
Regulatory and posture
- Categories
- Recovery, Immune
- Aliases
- Lysine-Proline-Valine, α-MSH (11-13) tripeptide
- Evidence posture
- preclinical - Mostly rodent colitis and dermatitis data. Human clinical evidence for KPV itself is limited.
- Regulatory status
- No FDA-approved KPV drug label. KPV is the C-terminal tripeptide fragment of α-MSH and is studied as an anti-inflammatory compound, primarily in animal models of colitis and dermatitis.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: Dalmasso 2008 PepT1-mediated KPV tripeptide intestinal-inflammation study (Gastroenterology)
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.